Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Novartis
Moodys
Federal Trade Commission
Accenture
Chinese Patent Office
Queensland Health
Fish and Richardson
Colorcon

Generated: October 20, 2017

DrugPatentWatch Database Preview

Concordia Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for CONCORDIA PHARMS INC, and what generic alternatives to CONCORDIA PHARMS INC drugs are available?

CONCORDIA PHARMS INC has twelve approved drugs.

There are two US patents protecting CONCORDIA PHARMS INC drugs.

There are sixty patent family members on CONCORDIA PHARMS INC drugs in thirty-eight countries and thirty-seven supplementary protection certificates in nine countries.

Summary for Applicant: Concordia Pharms Inc

International Patents:60
US Patents:2
Tradenames:13
Ingredients:11
NDAs:12
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc
DUTOPROL
hydrochlorothiazide; metoprolol succinate
TABLET, EXTENDED RELEASE;ORAL021956-002Aug 28, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-004Sep 28, 2010DISCNYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
DIBENZYLINE
phenoxybenzamine hydrochloride
CAPSULE;ORAL008708-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
JENLOGA
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-002May 25, 2010DISCNYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
LANOXIN
digoxin
TABLET;ORAL020405-001Sep 30, 1997RXYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
LANOXIN
digoxin
TABLET;ORAL020405-004Sep 30, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
JENLOGA
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-001Sep 30, 2009DISCNYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-002Jun 1, 2006ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Concordia Pharms Inc
DYRENIUM
triamterene
CAPSULE;ORAL013174-001Approved Prior to Jan 1, 1982RXYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms Inc
NILANDRON
nilutamide
TABLET;ORAL020169-002Apr 30, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Concordia Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-001Jun 1, 2006► Subscribe► Subscribe
Concordia Pharms Inc
JENLOGA
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-001Sep 30, 2009► Subscribe► Subscribe
Concordia Pharms Inc
UROXATRAL
alfuzosin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021287-001Jun 12, 2003► Subscribe► Subscribe
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-003Sep 28, 2010► Subscribe► Subscribe
Concordia Pharms Inc
KAPVAY
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-004Sep 28, 2010► Subscribe► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-002Jun 1, 2006► Subscribe► Subscribe
Concordia Pharms Inc
JENLOGA
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-002May 25, 2010► Subscribe► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-003Jun 1, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CONCORDIA PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
clonidine hydrochloride
Extended-release Tablets0.1 mg and 0.2 mg
KAPVAY
3/4/2011
clonidine hydrochloride
Extended-release Tablets0.1 mg and 0.2 mg
JENLOGA
3/4/2011
prednisolone sodium phosphate
Orally Disintegrating Tablets10 mg, 15 mg and 30 mg
ORAPRED
7/22/2010
alfuzosin hydrochloride
Extended-release Tablets10 mg
UROXATRAL
6/12/2007

International Patent Family for Concordia Pharms Inc Drugs

Country Document Number Estimated Expiration
Japan3797388► Subscribe
African Regional IP Organization (ARIPO)1107► Subscribe
Canada2264250► Subscribe
Slovakia27099► Subscribe
Iceland4964► Subscribe
European Patent Office0938318► Subscribe
Australia1922000► Subscribe
Hungary228007► Subscribe
Turkey9900289► Subscribe
China1543954► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Concordia Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90062-5Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C0108Belgium► SubscribePRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
15/009Ireland► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
C0041France► SubscribePRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Federal Trade Commission
Julphar
Express Scripts
Harvard Business School
Merck
Mallinckrodt
AstraZeneca
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot